Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Cana…
$40.48-1.26%
报价 2026-11-13
市值
$3.98B
EV
$4.98B
PE (TTM)
–
预期 PE
–
52 周区间距高点 -43.0%
$33.49$70.96
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| XENEXenon Pharmaceuticals Inc. | $3.98B | -1.3% | – | 0% | – | – | – | |
| TNGXTango Therapeutics, Inc. | $4.32B | +2.6% | -90.3% | 98.3% | – | – | – | |
| CRSPCRISPR Therapeutics AG | $4.1B | -0.9% | – | -1,534.4% | – | – | – | |
| RLAYRelay Therapeutics, Inc. | $4B | +0.1% | -23.4% | 89.7% | – | – | – | |
| TARSTarsus Pharmaceuticals, Inc. | $3.96B | +4.4% | +66.9% | 90.6% | – | – | 63.5x | |
| AMLXAmylyx Pharmaceuticals, Inc. | $3.89B | +1.4% | -99.9% | 0% | – | – | – | |
| ABCLAbCellera Biologics Inc. | $3.75B | -1.1% | – | 75% | – | – | – | |
| VKTXViking Therapeutics, Inc. | $3.73B | +5.9% | +380.0% | 0% | – | – | – | |
| ELVNEnliven Therapeutics, Inc. | $3.59B | +1.0% | – | 0% | – | – | – | |
| 同行中位数 | – | – | -23.4% | 37.5% | – | – | 63.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。